Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Charlotte Ebsen Paaskesen & Michael Borre. (2008) Body mass index and prognostic markers at radical prostatectomy. Scandinavian Journal of Urology and Nephrology 42:3, pages 230-236.
Read now
Read now
Karin Sennfält, Per Carlsson, Gabriel Sandblom & Eberhard Varenhorst. (2004) The estimated economic value of the welfare loss due to prostate cancer pain in a defined population. Acta Oncologica 43:3, pages 290-296.
Read now
Read now
Articles from other publishers (16)
Akhil Chopra, Mina Georgieva, Gilberto Lopes, Chong Ming Yeo & Benjamin Haaland. (2017) Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison. The Prostate 77:6, pages 639-646.
Crossref
Crossref
Ravishankar Jayadevappa, Sumedha Chhatre, Joseph J. Gallo, Marsha Wittink, Knashawn H. Morales, S. Bruce Malkowicz, David Lee, Thomas Guzzo, Adele Caruso, Keith Van Arsdalen, Alan J. Wein & J. Sanford Schwartz. (2015) Treatment preference and patient centered prostate cancer care: Design and rationale. Contemporary Clinical Trials 45, pages 296-301.
Crossref
Crossref
Ravishankar Jayadevappa, S. Bruce Malkowicz, Sumedha Chhatre, Joseph Gallo & J. Sanford Schwartz. (2010) Racial and ethnic variation in health resource use and cost for prostate cancer. BJU International 106:6, pages 801-808.
Crossref
Crossref
Ravishankar Jayadevappa, J Sanford Schwartz, Sumedha Chhatre, Alan J. Wein & S. Bruce Malkowicz. (2010) Association between utility and treatment among patients with prostate cancer. Quality of Life Research 19:5, pages 711-720.
Crossref
Crossref
Michael Borre. (2009) Screening by lower urinary tract symptoms vs asymptomatic prostate-specific antigen levels leading to radical prostatectomy in Danish men: tumour characteristics and treatment outcome. BJU International 104:2, pages 205-208.
Crossref
Crossref
Laurent Molinier, Eric Bauvin, Christophe Combescure, Christel Castelli, Xavier Rebillard, Michel Soulié, Jean-Pierre Daurès & Pascale Grosclaude. (2008) Methodological Considerations in Cost of Prostate Cancer Studies: A Systematic Review. Value in Health 11:5, pages 878-885.
Crossref
Crossref
Ravishankar Jayadevappa, Sumedha Chhatre, Mark Weiner, Bernard S. Bloom & S. Bruce Malkowicz. (2005) Medical care cost of patients with prostate cancer. Urologic Oncology: Seminars and Original Investigations 23:3, pages 155-162.
Crossref
Crossref
Christopher S. Saigal & Mark S. Litwin. (2002) The Economic Costs of Early Stage Prostate Cancer. PharmacoEconomics 20:13, pages 869-878.
Crossref
Crossref
Hirsch S. Ruchlin & James M. Pellissier. (2001) An economic overview of prostate carcinoma. Cancer 92:11, pages 2796-2810.
Crossref
Crossref
Eric J. Sherman, David G. Pfister, Hirsch S. Ruchlin, David M. Rubin, Mark H. Radzyner, Geralyn H. Kelleher, Susan F. Slovin, William K. Kelly & Howard I. Scher. (2001) The collection of indirect and nonmedical direct costs (COIN) form. Cancer 91:4, pages 841-853.
Crossref
Crossref
Bernard Candas, Lionel Cusan, Jose-Luis Gomez, Pierre Diamond, Raul E. Suburu, Jacques L�vesque, Ghislain Brousseau, Alain B�langer & Fernand Labrie. (2000) Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. The Prostate 45:1, pages 19-35.
Crossref
Crossref
MICHAEL BORRE, BIRGITTE STAUSB??L-GR??N & JENS OVERGAARD. (2000) p53 ACCUMULATION ASSOCIATED WITH bcl-2, THE PROLIFERATION MARKER MIB-1 AND SURVIVAL IN PATIENTS WITH PROSTATE CANCER SUBJECTED TO WATCHFUL WAITING. The Journal of Urology, pages 716-721.
Crossref
Crossref
MICHAEL BORRE, BIRGITTE STAUSBØL-GRØN & JENS OVERGAARD. (2000) p53 ACCUMULATION ASSOCIATED WITH bcl-2, THE PROLIFERATION MARKER MIB-1 AND SURVIVAL IN PATIENTS WITH PROSTATE CANCER SUBJECTED TO WATCHFUL WAITING. Journal of Urology 164:3 Part 1, pages 716-721.
Crossref
Crossref
P.M.M. Beemsterboer, H.J. de Koning, E. Birnie, P.J. van der Maas & F.H. Schr�der. (1999) Advanced prostate cancer: Course, care, and cost implications. The Prostate 40:2, pages 97-104.
Crossref
Crossref
Michael Borre, Morten Høyer, Benni Nerstrøm & Jens Overgaard. (1998) DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure. The Prostate 36:4, pages 244-249.
Crossref
Crossref
MICHAEL BORRESOREN M. BENTZENBENNI NERSTROMJENS OVERGAARD. (1998) TUMOR CELL PROLIFERATION AND SURVIVAL IN PATIENTS WITH PROSTATE CANCER FOLLOWED EXPECTANTLY. Journal of Urology 159:5, pages 1609-1614.
Crossref
Crossref